Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension

NCT01508026 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01508026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01508026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
May 31, 2013
Enrollment
4,161 (actual)
Sites
413

Conditions

As the registry lists them; a condition with its own page is linked.

stage 1 hypertension, stage 2 hypertension